



MOLECULAR PHARMACOLOGY



☐ 25 TO 100 GENES ☐ MULTIPLE CELLS / ORGANS



BETTER PRODUCT CANDIDATES



☐5 TO 15 GENES ☐SMALL BLOOD SAMPLES



ACCURATE CLINICAL DEVELOPMENT

FIG. 1


HEALTH PROFILES


INDIVIDUALIZED MEDICINE

☐100 TO 500 GENES ☐SMALL BLOOD SAMPES




BETTER HEALTH CARE MANAGEMENT






Barrell



, E. ...





41. ye.

FIG. 5

A 100 A

œ






. .

EACH NEW RECORD IMPROVES THE PREDICTIVE POWER OF THE DATABASE AND INCREASES ITS VALUE

∹.

FIG. 7



.





FIG. 9

PHASE TWO CLINICAL TRIAL DESIGN USING SELECTED PROFILING



- -THE TARGET CLINICAL POPULATION CAN BE EVALUATED FOR RESPONSIVENESS TO THERAPY BY FOCUSING ON DRUG RESPONSE GENE PROFILING
- NON-RESPONDERS FROM THE SECOND PORTION OF THE -"SIGNAL TO NOISE" CAN BE ENHANCED BY REMOVING

. i.

-DOSE CAN BE OPTIMIZED ON AN INDIVIDUAL BASIS TO MAXIMIZE THE IMPACT ON THERAPEUTIC OUTCOME


DOUBLE BLIND PLACEBO CONTROLLED PORTION


CLINICAL RESPONSE/NON-RESPONSE CAN BE CORRELATED

- CLINICAL EFFICACY CAN BE MEASURED WITH GREATER WITH DISEASE RESPONSE GENE PROFILING
 - **PRECISION**
- FUTURE STUDIES CAN BE PLANNED WITH GREATER CERTAINTY AND STATISTICAL POWER
- IMPORTANT INFORMATION REGARDING COMPETITIVE POSITIONING COMPARISION WITH CLINICAL DATABASES CAN PROVIDE RELATIVE TO EXISTING THERAPIES

FIG. 10b

FIG. 10a













FIG. 12a














































FIG. 19b





COMPARATIVE HERBAL PROFILING SHOWS DIFFERENCES AMONG ANTI-INFLAMMATORY HERBS SUCH AS ECHINACEA, ARNICA AND SIBERIAN GINSENG



RELATIVE mRNA EXPRESSION


31/49






33/49

SELECTED PROFILES REVEAL CONTAMINATION WITH ENDOTOXIN AMONG DIFFERENT COMMERCIAL BRANDS AS REVEALED IN SPM010 AND SPM016




RELATIVE mRNA EXPRESSION


FIG. 24



35/49





36/49





RELATIVE mRNA EXPRESSION

FIG. 25c













42/49 FIG. 29b □IN VITRO TREATMENT OF WHOLE BLOOD □IN VIVO COMPARISON OF CALIBRATED PROFILE DATA SETS (USING INFLAMMATION SELECTED PANEL SUBSET) AFTER IN-VITRO AND IN-VIVO DRUG EXPOSURE (STEROIDS)--STUDY 2 MADI 07-92H 6-9MM un[-o COXS AUGUST 2000 **SUBJECT 1JC** TNF-a IEN-Y ור-10 8-71 11-1B ור-גומ 0.001 10.000-1.000 0.010 0.100 **ИБЕГАТІЛЕ МЯМА ЕХРЯЕ**










ANAm avitajaa

EXAMPLE USE OF THE HUMAN LIVER SELECTED PANEL






FIG. 35

